TherapeuticsMD (TXMD) Misses Q2 EPS by 6c, Revenues Beat; Raises Q3 & FY19 Revenue Guidance
Tweet Send to a Friend
TherapeuticsMD (NASDAQ: TXMD) reported Q2 EPS of ($0.23), $0.06 worse than the analyst estimate of ($0.17). Revenue for the quarter ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
